Anti-complementary activity-guided fractionation of the ethanolic extract of Prunella vulgaris spikes led to the isolation of a new, unusual ∆ 11(12) triterpene, 3β,13β-dihydroxyolic-11-ene-28-oic acid (1), along with thirteen known triterpenes (2-14). The structure of the new compound was established by 1D and 2D NMR spectroscopic analysis. All the isolates were evaluated for their anti-complementary activity against the classical pathway (CP) and alternative pathway (AP). Eight triterpenes (1-8) showed anti-complementary activity against CP and AP, with CH 50 and AP 50 values of 0.15-0.37 mg/mL, and 0.29-0.53 mg/mL, respectively. Mechanism study using complement-depleted sera showed that oleanolic acid (2) acted selectively on C1q, C5, and C9 components, while 2αhydroxy oleanolic acid (3) interacted with C1q, C3, C5 and C9, and 2α,3α-dihydroxyolic-12-ene-28-oic acid (4) blocked C1q, C2, C3, C5 and C9.
The complement system is well recognized for its important role in host immune defense against infection and in the clearance of antigen-antibody complexes formed in blood and other tissues. It can be activated by three distinct pathways: the classical pathway (CP), the alternative pathway (AP), and the mannan binding lectin pathway (MBL-P) [1] . Inappropriate activation of the complement system is a potential pathogenesis of a variety of diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and acute respiratory distress syndrome (ARDS) [2] [3] [4] .
The desirable properties of an applicable anti-complementary therapeutic agent are that it should be inexpensive and highly specific, either having a long plasma half-life or be active orally [5] . However, none of the currently available agents meets all these criteria. For example, Cobra venom factor (CVF), the first anticomplementary agent, was demonstrated to be ineffective because of a strong immune response with generation of neutralizing antibodies in the recipient, and of side effects in treatment of bacterial and viral infections [6] . Synthetic nafamastat mesilate (FUT-175) has been used as an effective protease inhibitor in treatment of complement-related diseases. Unfortunately, it was found to have detrimental consequences in patients due to nonspecific effects [7] . A recombinant humanized antibody fragment that inhibits at specific points in the complement cascade has been discovered and used successfully in man [8] . However, the protein drugs may not exert their full anti-complement effect due to several drawbacks, such as being expensive to produce, difficult to formulate, potentially immunogenic, and having poor oral bioavailability and tissue penetration [8] . This motivates the screening of natural products for anti-complementary agents that might offer a relatively inexpensive and non-toxic alternative for the potential prevention and treatment of complement-related diseases [9] .
Prunella vulgaris L. (Labiatae/Lamiaceae) is a perennial plant that is widely distributed in China, Japan, Korea and Europe. The spikes of the plant have long been used as a traditional Chinese medicine (TCM) for its distinct "heat-clearing" effect. Pharmacological studies have demonstrated that the herb possesses immune modulating [10] , antioxidant, antiviral, antibacterial [11] , antiinflammatory and anti-allergic activities [12] , some of which might be closely related to a complement inhibition effect [13] [14] [15] . Our preliminary experiment showed that the ethanolic extract of P. vulgaris spikes had reproducible inhibitory activity against CP (CH 50 = 0.41 ± 0.09 mg/mL). As part of our continuous effort to search for anti-complementary agents from TCM [16, 17] , this study was undertaken to 1) isolate and identify the potential anticomplement compounds from P. vulgaris spikes by bioactivityguided fractionation; 2) evaluate the anti-complementary activities of the isolates through the CP and AP; and 3) identify the targets of the active compounds in the complement activation cascade.
The 95% ethanol extract of P. vulgaris spikes was suspended in water and extracted successively with light petroleum, EtOAc, and n-BuOH. Repeated column chromatography of the anticomplementary EtOAc fraction led to the isolation of a new ∆ 11 (12) triterpene (3β,13β-dihydroxyolic-11-ene-28-oic acid, 1), along with thirteen known ones (2-14). , nine methylene carbons, and seven methyl carbons. These data suggested 1 to be a triterpene with an oleanane skeleton [18] , though a double bond and a tertiary hydroxy group remained unassigned. Placement of the tertiary hydroxy at C-13 in 1 was facilitated by the observation of HMBC correlations between H-18 and C-13/C-17/C-28, and between H-15/H-27 and C-13. The location of the double bond at Δ 11 (12) was determined by the diagnostic HMBC correlations from H-12 (δ 6.03, br d, J = 10.7 Hz) to C-11 and C-13. In addition, a comparison of the NMR data of 1 and 3β,13β-dihydroxyurs-11-ene-28-oic acid (a Δ 11 (12) triterpene) [19] revealed that their carbon signals of C-11-14 were almost identical, confirming the presence of an unusual Δ 11 (12) double bond in 1. The hydroxyl at C-3 was assigned to be of β-orientation, as indicated by the coupling constant (J = 11.5 Hz) between H-3 and H-2β [20, 21] . The 13β-OH configuration was preferred due to the trans fused C/D rings in the oleanane triterpene series, and further strengthened by NMR data comparison of 1 ( It is well known that triterpenes usually contain the endocyclic double bond at C-12 and C-13, whereas in 1, the double bond is located at C-11 and C-12. The Δ 11 (12) triterpenes are not commonly found in natural products and have been reported only in Malus pumila (3β,13β-dihydroxyurs-11-en-28-oic acid and 2α,3β,13βtrihydroxyurs-11-en-28-oic acid) [22] , Fatsia polycarpa (fatsicarpain G and 3α-hydroxyolean-11-en-28,13β-olide) [23] , and Eucalyptus camaldulensis var. obtusa (3β-hydroxyurs-11-en-28,13β-olide and 2α,3β,7β-trihydroxyurs-11-en-28,13β-olide) [24, 25] . In addition, some Δ 11(12), 13 (18) dien-and 13,27-cyclo-Δ 11 (12) triterpenes (mainly present in Bupleurum species) contain the Δ 11 (12) part [26, 27] .
Compounds 2-14 were identified as oleanolic acid (2) [28], 2αhydroxyoic acid (3) [28] , 2α,3α-dihydroxyolic-12-ene-28-oic acid (4) [29] , ursolic acid (5) [28] , 2α-hydroxy ursolic acid (6) [28] , 2α,3α-dihydroxyurs-12-ene-28-oic acid (7) [29] , 2α,3α,23trihydroxyurs-12-ene-28-oic acid (8) [29] , lupeol (9) [30] , 2α,3βdihydroxy-lup-20(29)-ene (10) [30] , lupenone (11) [31] , chiratenol (12) [32] , β-amyrenone (13) [33] and uvaol (14) [34] , respectively, by comparison of their 1 H and 13 C NMR spectroscopic data with those reported in the literature. Compounds 9-13 were isolated from P. vulgaris for the first time.
All the isolated triterpenes were tested for their anti-complementary activities against the CP and AP with heparin as the positive control. As shown in Table 2 , eight triterpenes (1-8) exhibited anticomplementary activity with CH 50 and AP 50 values of 0.15-0.37 mg/mL, and 0.29-0.53 mg/mL, respectively. Compounds 10-14 had no inhibitory effect towards either CP or AP. It was found that triterpenes bearing a carboxylic acid group at C-28 showed an inhibitory effect, while those with a CH 3 (12 and 13) or CH 2 OH group at C-28 (14) , and lupeol derivatives (10 and 11) lost the activity. The carboxylic acid group at C-28 appears to be essential for the complement-inhibiting activity of triterpenes, as reported previously [35, 36] . In addition, the results indicated that triterpenes with adjacent hydroxyl groups at C-2 and C-3 (3-4, and 6-8) showed stronger anti-complementary activity than those with only one hydroxyl group at C-3 (1-2 and 5).
No. 1 In order to understand the anti-complementary mechanism of these active compounds in P. vulgaris, three oleane-type triterpenes (2) (3) (4) were selected to identify their target components in the complement activation cascade using complement-depleted (C-depleted) sera.
As shown in Figure 3 , oleanolic acid (2) did not regain the hemolytic activities of C1q-, C5-and C9-depleted sera. The hemolysis percentages of the above C-depleted sera were only 9.9 ± 1.2%, 7.6 ± 1.7% and 8.8 ± 2.0%, respectively.
However, hemolysis was observed in C2-, C3-and C4-depleted sera (83.7 ± 5.1%, 84.9 ± 4.5% and 94.9 ± 5.1%, respectively). The result indicated that 2 interacts selectively with C1q, C5 and C9, but not with C2, C3 and C4. Similarly, 3 and 4 were found to inhibit C1q, C3, C5 and C9, and C1q, C2, C3, C5 and C9 of the complement system, respectively. Taken together with the structural characters of 2-4, the different stereochemistry of 3-OH and the presence of adjacent hydroxyls might be the key factor for binding to the different target components of the complement system. This is the first report on the identification of targets of triterpenoids on the complement activation cascade. [25] [26] [27] [28] [29] [30] . Heparin (sodium salt, 160 IU/mg) was purchased from Sigma-Aldrich. Anti-C1q, Human (Goat); Anti-C2, Human (Goat); Anti-C5, Human (Rabbit) and Anti-C9, Human (Goat) were obtained from Merck Biosciences (Shanghai, China). Anti-C3, Human (Goat) and Anti-C4, Human (Goat) were purchased from Shanghai Sun Biotech Co. Ltd. The isotonic veronal-buffered saline (VBS 2+ ) buffer contained 0.5 mM Mg 2+ and 0.15 mM Ca 2+ . The veronal buffer saline (EGTA-VB) buffer contained 5 mM Mg 2+ and 8 mM EGTA. All other chemical reagents were of analytical grade. 
Extraction and isolation:
The dried and pulverized P. vulgaris spikes (14 kg) were extracted with 95% ethanol (50 L × 3) at room temperature. The ethanolic extracts were combined and evaporated to dryness under reduced pressure to afford a dark green residue (700 g). The residue was then suspended in water (1000 mL) and partitioned successively with light petroleum (PE) (60-90°C, 1000 mL × 3), EtOAc (1000 mL × 3) and n-BuOH (1000 mL × 3) to yield 3 corresponding extracts (250 g, 200 g and 120 g). All 3 extracts were tested for anti-complementary activity against the CP, but only the EtOAc extract showed inhibitory activity (CH 50 = 0.38 ± 0.08 mg/mL).
Part (160 g) of the EtOAc extract was separated by silica gel CC eluted with a gradient solvent system of PE-acetone (50:1, 20:1, 10:1, 5:1, 2:1, and 1:1) to yield 6 fractions A-F. Fraction B (25 g)
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was subjected to silica gel CC eluted with a gradient of PE-EtOAc (30:1, 20:1, 10:1, 5:1, and 1:1) to afford 5 fractions, B 1-5 . Fraction B 1 (7 g) was further chromatographed by silica gel CC with PE-EtOAc (20:1) to yield compounds 11 (18 mg) and 12 (12 mg) . Fraction B 2 (4 g) was chromatographed by silica gel CC with PEacetone (25:1) to yield compounds 13 (10 mg) and 14 (15 mg) . Fraction B 4 (5 g) was purified by CC on silica gel PE-acetone (20:1), followed by purification on Sephadex LH-20 (CHCl 3 -MeOH, 1:1) to yield compounds 9 (13 mg) and 10 (11 mg). Fraction C (36 g) was fractionated by passage through a silica gel column with a gradient of PE-EtOAc (30:1, 20:1, 10:1, 5:1, and 1:1) to yield 5 fractions, C 1-5 . Fraction C 2 (8.2 g) was then chromatographed by silica gel CC with PE-EtOAc (15:1) to yield 2 (200 mg) and 5 (26 mg) . Fraction C 3 (7.9 g) was subjected to silica gel CC by elution with PE-EtOAc mixtures of increasing polarity (10:1) to yield 1 (8 mg) . Fraction D (30 g) was subjected to CC on silica gel with a gradient of PE-EtOAc (20:1, 10:1, 5:1, 2:1, and 1:1) to give 5 fractions, D 1-5 . Fraction D 3 (6 g) was then purified by silica gel CC with PE-EtOAc (8:1) to yield 3 (17 mg), 4 (16 mg), 6 (9 mg) and 7 (11 mg) . Fraction D 4 (3 g) was separated by repeated silica gel CC with PE-EtOAc (5:1) to yield 8 (9 mg).
Anti-complementary activity through the classical pathway:
The anti-complementary assay through the CP was conducted according to Mayer's modified method [37] . In brief, sensitized erythrocytes (EA) were prepared by incubation of sheep erythrocytes (4.0 × 10 8 cells/mL) with rabbit anti-sheep erythrocyte antibody in VBS 2+ . 
Anti-complementary activity through the alternative pathway:
The anti-complementary assay through the AP was measured according to Klerx's method [38] . Briefly, each sample was dissolved in EGTA-VB, and serial dilutions of the samples were prepared by adding appropriate volumes of EGTA-VB. After preincubation of each sample (150 μL) with 1:10 diluted NHS (150 μL) at 37°C for 10 min, 200 μL rabbit erythrocytes (ERs 3.0 × 10 8 cells/mL) were added, followed by a second incubation at 37°C for 30 min. After reaction, the resulting mixture was centrifuged immediately, and the optical density of the supernatant was then measured at 405 nm.
Identification of the targets on the complement activation cascade:
Tests to identify the targets on the complement activation cascade were conducted according to the modified method of Zhou et al [39] . Samples were dissolved in DMSO, and diluted in VBS 2+ to the required concentration. The concentrations of 2-4 were 1.46, 1.17 and 0.92 mg/mL, respectively, which were just sufficient to completely inhibit the hemolysis of 1:10 diluted NHS through CP. Two hundred μL EAs and 200 μL individual complement-depleted sera of C1q, C2, C3, C4, C5 or C9 were added to 200 μL sampletreated NHS, and the mixture was incubated at 37ºC for 30 min. After centrifugation and measurement of the optical density of the supernatant, the percentage of hemolysis was calculated. For the assay of the individual depleted serum group, C-depleted sera were directly incubated with EAs under the same conditions, and the hemolytic activities were calculated. 
